Oral deucrictibant for prophylaxis lowers hereditary angioedema attack rate by 83%translating…

Patients with hereditary angioedema receiving daily deucrictibant extended-release tablets as long-term prophylactic therapy had a reduced monthly attack rate vs. placebo of 83%, according to topline data from a phase 3 study.